{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T09:45:48Z","timestamp":1782726348014,"version":"3.54.5"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Allogeneic hematopoietic cell transplantation (HCT) is a potential cure for patients with peripheral T-\/NK-cell lymphomas (PTCL), but its application is understudied. This prospective trial evaluates a unique reduced-intensity (RIC) transplantation platform in 31 patients with PTCL (NCT03922724). One-year progression-free survival, the primary endpoint, is 53% (95% CI 29-72%) on the RIC arm and 60% (95% CI 25-83%) on the modified-RIC arm. The 3-year overall survival is 61% (95% CI 42-76%), with relapse estimated at 18% (95% CI 6-34%) at 3 years. Transplant-related mortality was 24% (95% CI 10-41%) at 1-year, low at 11% (95% CI 2-29%) for patients \u226460 years but 56% (95% CI 17-82%) for patients &gt;60 years,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.01. There was no grade III-IV acute graft-versus-host disease, while chronic graft-versus-host disease was estimated at 23% (95 CI 10-38%) at 2 years. This study demonstrates a benefit regardless of pre-transplantation disease status, challenging the requirement of remission for HCT.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-71461-5","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T06:55:32Z","timestamp":1776927332000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Allogeneic hematopoietic cell transplantation in mature T- or NK-lymphomas: a phase II clinical trial"],"prefix":"10.1038","volume":"17","author":[{"given":"Kamil A.","family":"Rechache","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia S.","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Sponaugle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Combs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessenia","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8018-2366","authenticated-orcid":false,"given":"Xingmin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis A.","family":"Flomerfelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalpana","family":"Upadhyaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Telford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Muhammad Salman","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Peluso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christi","family":"McKeown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Stokes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Napier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruby","family":"Sabina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Wilder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy","family":"Baruffaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Cuellar-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Gea-Banacloche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary M.","family":"Czech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa A.","family":"Hyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.","family":"Kanakry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4868-6852","authenticated-orcid":false,"given":"Dimana","family":"Dimitrova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9522-3618","authenticated-orcid":false,"given":"Jennifer A.","family":"Kanakry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,23]]},"reference":[{"key":"71461_CR1","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow, S. H. et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127, 2375\u20132390 (2016).","journal-title":"Blood"},{"key":"71461_CR2","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","volume":"124","author":"F Ellin","year":"2014","unstructured":"Ellin, F., Landstrom, J., Jerkeman, M. & Relander, T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish lymphoma registry. Blood 124, 1570\u20131577 (2014).","journal-title":"Blood"},{"key":"71461_CR3","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1007\/s00277-019-03694-y","volume":"98","author":"A Janikova","year":"2019","unstructured":"Janikova, A. et al. First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients. Ann. Hematol. 98, 1961\u20131972 (2019).","journal-title":"Ann. Hematol."},{"key":"71461_CR4","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1159\/000500666","volume":"143","author":"F Lansigan","year":"2020","unstructured":"Lansigan, F. et al. Outcomes for relapsed and refractory peripheral T-cell lymphoma patients after front-line therapy from the COMPLETE registry. Acta Haematol. 143, 40\u201350 (2020).","journal-title":"Acta Haematol."},{"key":"71461_CR5","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.3324\/haematol.2017.186577","volume":"103","author":"M Bellei","year":"2018","unstructured":"Bellei, M. et al. The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, international T-cell project. Haematologica 103, 1191\u20131197 (2018).","journal-title":"Haematologica"},{"key":"71461_CR6","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41375-020-0791-3","volume":"35","author":"SY Chen","year":"2021","unstructured":"Chen, S. Y. et al. Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK\/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making. Leukemia 35, 130\u2013142 (2021).","journal-title":"Leukemia"},{"key":"71461_CR7","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1200\/JCO.2011.37.3647","volume":"31","author":"M Federico","year":"2013","unstructured":"Federico, M. et al. Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project. J. Clin. Oncol. 31, 240\u2013246 (2013).","journal-title":"J. Clin. Oncol."},{"key":"71461_CR8","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1002\/cam4.5248","volume":"12","author":"C Wei","year":"2023","unstructured":"Wei, C. et al. Clinicopathologic characteristics, outcomes, and prognostic factors of angioimmunoblastic T-cell lymphoma in China. Cancer Med. 12, 3987\u20133998 (2023).","journal-title":"Cancer Med."},{"key":"71461_CR9","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose, J., Armitage, J., Weisenburger, D. & International, T. C. L. P. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J. Clin. Oncol. 26, 4124\u20134130 (2008).","journal-title":"J. Clin. Oncol."},{"key":"71461_CR10","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/annonc\/mdq359","volume":"22","author":"G Gutierrez-Garcia","year":"2011","unstructured":"Gutierrez-Garcia, G. et al. Comparison of four prognostic scores in peripheral T-cell lymphoma. Ann. Oncol. 22, 397\u2013404 (2011).","journal-title":"Ann. Oncol."},{"key":"71461_CR11","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13045-016-0266-1","volume":"9","author":"C Pellegrini","year":"2016","unstructured":"Pellegrini, C. et al. A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed\/refractory peripheral T-cell lymphoma patients. J. Hematol. Oncol. 9, 38 (2016).","journal-title":"J. Hematol. Oncol."},{"key":"71461_CR12","doi-asserted-by":"publisher","first-page":"285","DOI":"10.6004\/jnccn.2022.0015","volume":"20","author":"SM Horwitz","year":"2022","unstructured":"Horwitz, S. M. et al. T-cell lymphomas, version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. 20, 285\u2013308 (2022).","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"71461_CR13","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/j.1365-2141.2010.08329.x","volume":"151","author":"A Simon","year":"2010","unstructured":"Simon, A. et al. Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP\/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. Br. J. Haematol. 151, 159\u2013166 (2010).","journal-title":"Br. J. Haematol."},{"key":"71461_CR14","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1002\/cncr.20999","volume":"103","author":"MP Escalon","year":"2005","unstructured":"Escalon, M. P. et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience. Cancer 103, 2091\u20132098 (2005).","journal-title":"Cancer"},{"key":"71461_CR15","doi-asserted-by":"publisher","first-page":"v108","DOI":"10.1093\/annonc\/mdv201","volume":"26","author":"F d\u2019Amore","year":"2015","unstructured":"d\u2019Amore, F. et al. Peripheral T-cell lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 26, v108\u2013v115 (2015).","journal-title":"Ann. Oncol."},{"key":"71461_CR16","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1016\/j.bbmt.2017.07.027","volume":"23","author":"MA Kharfan-Dabaja","year":"2017","unstructured":"Kharfan-Dabaja, M. A. et al. Clinical practice recommendations on indication and timing of hematopoietic cell transplantation in mature T cell and NK\/T cell lymphomas: an international collaborative effort on behalf of the guidelines committee of the American Society for Blood and Marrow Transplantation. Biol. Blood Marrow Transplant. 23, 1826\u20131838 (2017).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"71461_CR17","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/leu.2011.240","volume":"26","author":"A Dodero","year":"2012","unstructured":"Dodero, A. et al. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed\/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia 26, 520\u2013526 (2012).","journal-title":"Leukemia"},{"key":"71461_CR18","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1200\/JCO.2008.20.4628","volume":"27","author":"C Kyriakou","year":"2009","unstructured":"Kyriakou, C. et al. Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. J. Clin. Oncol. 27, 3951\u20133958 (2009).","journal-title":"J. Clin. Oncol."},{"key":"71461_CR19","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.bbmt.2013.01.006","volume":"19","author":"JA Kanakry","year":"2013","unstructured":"Kanakry, J. A. et al. Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma. Biol. Blood Marrow Transplant. 19, 602\u2013606 (2013).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"71461_CR20","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1200\/JCO.2007.14.1366","volume":"26","author":"S Le Gouill","year":"2008","unstructured":"Le Gouill, S. et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J. Clin. Oncol. 26, 2264\u20132271 (2008).","journal-title":"J. Clin. Oncol."},{"key":"71461_CR21","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/j.1365-2141.2010.08210.x","volume":"150","author":"AR Shustov","year":"2010","unstructured":"Shustov, A. R. et al. Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas. Br. J. Haematol. 150, 170\u2013178 (2010).","journal-title":"Br. J. Haematol."},{"key":"71461_CR22","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1200\/JCO.2012.46.0188","volume":"31","author":"SM Smith","year":"2013","unstructured":"Smith, S. M. et al. Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J. Clin. Oncol. 31, 3100\u20133109 (2013).","journal-title":"J. Clin. Oncol."},{"key":"71461_CR23","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.21037\/atm-20-5546","volume":"9","author":"M Narkhede","year":"2021","unstructured":"Narkhede, M., Mehta, A., Ansell, S. M. & Goyal, G. CAR T-cell therapy in mature lymphoid malignancies: clinical opportunities and challenges. Ann. Transl. Med. 9, 1036 (2021).","journal-title":"Ann. Transl. Med."},{"key":"71461_CR24","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1186\/s13287-021-02595-0","volume":"12","author":"P Safarzadeh Kozani","year":"2021","unstructured":"Safarzadeh Kozani, P., Safarzadeh Kozani, P. & Rahbarizadeh, F. CAR-T cell therapy in T-cell malignancies: is success a low-hanging fruit? Stem Cell Res. Ther. 12, 527 (2021).","journal-title":"Stem Cell Res. Ther."},{"key":"71461_CR25","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","volume":"30","author":"G Ghilardi","year":"2024","unstructured":"Ghilardi, G. et al. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy. Nat. Med. 30, 984\u2013989 (2024).","journal-title":"Nat. Med."},{"key":"71461_CR26","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1182\/blood-2022-169336","volume":"140","author":"C Hosing","year":"2022","unstructured":"Hosing, C. et al. Post-allograft romidepsin maintenance mitigates relapse risk and stimulates the graft-versus-malignancy effect through enhanced NK-cell cytotoxicity in patients with aggressive T-cell malignancies in a phase I\/II trial. Blood 140, 1885\u20131886 (2022).","journal-title":"Blood"},{"key":"71461_CR27","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1182\/blood-2023-190213","volume":"142","author":"C Hosing","year":"2023","unstructured":"Hosing, C. et al. Post-allograft romidepsin maintenance mitigates relapse risk and stimulates the graft-versus-malignancy effect through enhanced NK-cell cytotoxicity in patients with T-cell malignancies: final results of a phase I\/II trial. Blood 142, 184 (2023).","journal-title":"Blood"},{"key":"71461_CR28","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1111\/trf.16411","volume":"61","author":"S Hassan","year":"2021","unstructured":"Hassan, S., West, K. A., Ward, W. W., Kanakry, J. A. & Flegel, W. A. Rebound and overshoot of donor-specific antibodies to human leukocyte antigens (HLA) during desensitization with plasma exchanges in hematopoietic progenitor cell transplantation: a case report. Transfusion 61, 1980\u20131986 (2021).","journal-title":"Transfusion"},{"key":"71461_CR29","doi-asserted-by":"publisher","unstructured":"Shanmugasundaram, K. et al. Safety but limited efficacy of donor lymphocyte infusion for post-transplantation cyclophosphamide-treated patients. Bone Marrow Transplant. https:\/\/doi.org\/10.1038\/s41409-024-02312-4 (2024).","DOI":"10.1038\/s41409-024-02312-4"},{"key":"71461_CR30","doi-asserted-by":"publisher","first-page":"e194","DOI":"10.1016\/S2352-3026(15)00045-9","volume":"2","author":"R Admiraal","year":"2015","unstructured":"Admiraal, R. et al. Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis. Lancet Haematol. 2, e194\u2013e203 (2015).","journal-title":"Lancet Haematol."},{"key":"71461_CR31","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.jcyt.2023.05.012","volume":"25","author":"AG Troullioud Lucas","year":"2023","unstructured":"Troullioud Lucas, A. G. et al. Early immune reconstitution as predictor for outcomes after allogeneic hematopoietic cell transplant; a tri-institutional analysis. Cytotherapy 25, 977\u2013985 (2023).","journal-title":"Cytotherapy"},{"key":"71461_CR32","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1182\/bloodadvances.2024014836","volume":"9","author":"R Admiraal","year":"2025","unstructured":"Admiraal, R. et al. Improved survival with model-based dosing of antithymocyte globulin in pediatric hematopoietic cell transplantation. Blood Adv. 9, 2344\u20132353 (2025).","journal-title":"Blood Adv."},{"key":"71461_CR33","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1007\/s11912-022-01310-3","volume":"24","author":"NC Foley","year":"2022","unstructured":"Foley, N. C. & Mehta-Shah, N. Management of peripheral T-cell lymphomas and the role of transplant. Curr. Oncol. Rep. 24, 1489\u20131499 (2022).","journal-title":"Curr. Oncol. Rep."},{"key":"71461_CR34","doi-asserted-by":"publisher","unstructured":"Shumilov, E. et al. Allogeneic stem cell transplantation for major T-cell lymphoma entities: an analysis of the EBMT-lymphoma working party. J. Hematol. Oncol. 19, https:\/\/doi.org\/10.1186\/s13045-026-01783-w (2026).","DOI":"10.1186\/s13045-026-01783-w"},{"key":"71461_CR35","doi-asserted-by":"publisher","first-page":"267 e261","DOI":"10.1016\/j.jtct.2022.12.009","volume":"29","author":"CH Sterling","year":"2023","unstructured":"Sterling, C. H. et al. Allogeneic blood or marrow transplantation with post-transplantation cyclophosphamide for peripheral T cell lymphoma: the importance of graft source. Transplant. Cell Ther. 29, 267 e261\u2013267 (2023).","journal-title":"Transplant. Cell Ther."},{"key":"71461_CR36","doi-asserted-by":"publisher","unstructured":"Shumilov, E. et al. Allogeneic stem cell transplantation against aggressive lymphomas: graft-versus-lymphoma effects in peripheral T-cell lymphoma and diffuse large B-cell lymphoma after myeloablative conditioning. Leuk. Lymphoma 1\u201312, https:\/\/doi.org\/10.1080\/10428194.2024.2438805 (2024).","DOI":"10.1080\/10428194.2024.2438805"},{"key":"71461_CR37","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1200\/JCO.2004.12.050","volume":"22","author":"P Corradini","year":"2004","unstructured":"Corradini, P. et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin\u2019s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J. Clin. Oncol. 22, 2172\u20132176 (2004).","journal-title":"J. Clin. Oncol."},{"key":"71461_CR38","doi-asserted-by":"publisher","first-page":"S431","DOI":"10.1016\/j.bbmt.2017.12.516","volume":"24","author":"N Dole","year":"2018","unstructured":"Dole, N., Luebbering, N., Gloude, N. J., Lane, A. & Davies, S. M. 593-IL-8 levels early after bone marrow transplant are associated with later complications of stem cell transplantation. Biol. Blood Marrow Transplant. 24, S431\u2013S432 (2018).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"71461_CR39","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1182\/blood-2017-05-782870","volume":"130","author":"NJ Gloude","year":"2017","unstructured":"Gloude, N. J. et al. Circulating dsDNA, endothelial injury, and complement activation in thrombotic microangiopathy and GVHD. Blood 130, 1259\u20131266 (2017).","journal-title":"Blood"},{"key":"71461_CR40","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1200\/JCO.2015.63.5540","volume":"34","author":"SV Adams","year":"2016","unstructured":"Adams, S. V., Newcomb, P. A. & Shustov, A. R. Racial patterns of peripheral T-cell lymphoma incidence and survival in the United States. J. Clin. Oncol. 34, 963\u2013971 (2016).","journal-title":"J. Clin. Oncol."},{"key":"71461_CR41","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","volume":"103","author":"A Gallamini","year":"2004","unstructured":"Gallamini, A. et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 103, 2474\u20132479 (2004).","journal-title":"Blood"},{"key":"71461_CR42","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror, M. L. et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106, 2912\u20132919 (2005).","journal-title":"Blood"},{"key":"71461_CR43","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1182\/bloodadvances.2017015487","volume":"2","author":"C de Koning","year":"2018","unstructured":"de Koning, C. et al. Filgrastim enhances T-cell clearance by antithymocyte globulin exposure after unrelated cord blood transplantation. Blood Adv. 2, 565\u2013574 (2018).","journal-title":"Blood Adv."},{"key":"71461_CR44","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2307\/2530286","volume":"38","author":"R Brookmeyer","year":"1982","unstructured":"Brookmeyer, R. & Crowley, J. A confidence-interval for the median survival-time. Biometrics 38, 29\u201341 (1982).","journal-title":"Biometrics"},{"key":"71461_CR45","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka, D. et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant. 15, 825\u2013828 (1995).","journal-title":"Bone Marrow Transplant."},{"key":"71461_CR46","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia, M. H. et al. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group Report. Biol. Blood Marrow Transplant. 21, 389\u2013401 (2015).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"71461_CR47","first-page":"177","volume":"18","author":"RA Cahill","year":"1996","unstructured":"Cahill, R. A., Spitzer, T. R. & Mazumder, A. Marrow engraftment and clinical manifestations of capillary leak syndrome. Bone Marrow Transplant. 18, 177\u2013184 (1996).","journal-title":"Bone Marrow Transplant."},{"key":"71461_CR48","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transplant. 25, 625\u2013638 (2019).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"71461_CR49","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1214\/aos\/1176350951","volume":"16","author":"RJ Gray","year":"1988","unstructured":"Gray, R. J. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann. Stat. 16, 1141\u20131154 (1988).","journal-title":"Ann. Stat."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71461-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71461-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71461-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T09:07:51Z","timestamp":1782724071000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71461-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,23]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["71461"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-71461-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,23]]},"assertion":[{"value":"23 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5606"}}